Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration | BMC Cancer | Full Text

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration | BMC Cancer | Full Text

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF.

Authors:Fei Liang, Sheng Zhang, Qin Wang and Wenfeng Li

Citation:BMC Cancer 2020 20:823

Content type:Research article

 

Published on: 31 August 2020

• ViewFull Text
 
• ViewPDF